清晨好,您是今天最早来到科研通的研友!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您科研之路漫漫前行!

Allogeneic transplantation in advanced cutaneous T-cell lymphomas (CUTALLO): a propensity score matched controlled prospective study

倾向得分匹配 医学 移植 造血干细胞移植 内科学 人口 蕈样真菌病 前瞻性队列研究 外科 淋巴瘤 环境卫生
作者
Adèle de Masson,M. Beylot‐Barry,C. Ram‐Wolff,Caroline Ram-Wolff,Stéphane Dalle,Stéphane Dalle,S. Oro,Saskia Ingen-Housz-Oro,Corentin Orvain,O. Dereure,Olivier Dereure,Amandine Charbonnier,Christine Longvert,Christine Longvert,Stéphane Barete,E. Wierzbicka-Hainaut,F. Aubin,Marie‐Thérèse Rubio,Marc Bernard,Marc Bernard
出处
期刊:The Lancet [Elsevier BV]
卷期号:401 (10392): 1941-1950 被引量:65
标识
DOI:10.1016/s0140-6736(23)00329-x
摘要

Advanced-stage cutaneous T-cell lymphomas (CTCLs) are rare, usually refractory, and fatal diseases. Case series have suggested that allogeneic haematopoietic stem cell transplantation (HSCT) might improve the prognosis of advanced-stage CTCLs. The objective of this study was to investigate the effect of allogeneic HSCT compared with non-HSCT therapy on the outcome of individuals with advanced-stage CTCLs.In this prospective, multicentre, matched controlled trial, conducted at 30 hospitals, participants with advanced CTCLs were allocated treatment: if they had an available compatible related donor they were assigned to allogeneic HSCT, or if not they were allocated to non-allogeneic HSCT therapy. Key inclusion criteria were participants aged 18-70 years, with advanced stage mycosis fungoides or Sézary syndrome, and at least one poor prognostic criteria. Participants were excluded if they were not in complete or partial remission of the disease. Propensity score 1:1 matching with replacement (ie, that each participant treated with HSCT was matched to the participant with the closest propensity score treated with non-HSCT therapy, even if they had already been matched) was used to handle confounding factors, with the balance of covariate distribution between HSCT and non-HSCT groups assessed using standardised mean differences. The primary endpoint was progression-free survival in the matched intention-to-treat population. This trial is registered with ClinicalTrials.gov (NCT02520908), and is currently active but not recruiting.From June 1, 2016, to March 3, 2022, total of 99 participants were enrolled at 17 centres in France. Participants with a sibling or matched unrelated donor were assigned to allogeneic HSCT (HSCT group, n=55 [56%]) and participants without a donor were assigned to non-allogeneic HSCT treatment (non-HSCT group, n=44 [44%]). The median follow-up among survivors was 12·6 months (IQR 11·0-35·2). In the HSCT group, 51 participants (93%) were 1:1 matched to participants from the non-HSCT group. In the intention-to-treat analysis, median progression-free survival was significantly longer in the HSCT group (9·0 months [95% CI 6·6-30·5]) than in the non-HSCT group (3·0 months [2·0-6·3]), with a hazard ratio of 0·38 (95% CI 0·21-0·69; p<0·0001). In the per-protocol population, 40 participants (78%) in the HSCT group had 101 serious events and 29 participants (67%) in the non-HSCT group had 70 serious adverse events. The most common serious adverse event other than graft-versus-host disease in both groups was infections, occurring in 30 participants (59%) in the HSCT group and in 19 participants (44%) in the non-HSCT group.Allogeneic HSCT was associated with significantly longer progression-free survival in participants with advanced-stage CTCLs. These results indicate that allogeneic HSCT treatment should be made available to individuals with high-risk, advanced-stage mycosis fungoides or Sézary syndrome who achieve pre-transplant disease remission.French Ministry of Health, National Cancer Institute, Programme Hospitalier de Recherche Clinique en Cancérologie.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
紧张的幼蓉完成签到,获得积分10
9秒前
29秒前
29秒前
文静飞松完成签到,获得积分10
40秒前
修渊完成签到 ,获得积分10
1分钟前
温暖的大船完成签到,获得积分10
1分钟前
波爷完成签到,获得积分10
1分钟前
科研通AI6.3的应助被amiee采纳,获得10
1分钟前
lianxin完成签到 ,获得积分10
1分钟前
ABC完成签到 ,获得积分10
1分钟前
1分钟前
云彦完成签到,获得积分10
2分钟前
李木禾完成签到 ,获得积分10
2分钟前
耍酷的雨泽完成签到,获得积分10
2分钟前
arniu2008的应助被科研通管家采纳,获得80
2分钟前
2分钟前
2分钟前
2分钟前
打打的应助被科研通管家采纳,获得10
2分钟前
2分钟前
甜美达完成签到 ,获得积分10
2分钟前
Panda2022完成签到,获得积分10
2分钟前
范白容完成签到 ,获得积分0
2分钟前
2分钟前
Aria发布了新的文献求助10
2分钟前
王志新完成签到 ,获得积分10
3分钟前
Panda2022发布了新的文献求助30
3分钟前
3分钟前
舒服的月饼完成签到 ,获得积分10
3分钟前
chen发布了新的文献求助10
3分钟前
可爱的一兰完成签到,获得积分10
3分钟前
3分钟前
wuyouping完成签到,获得积分10
3分钟前
amiee发布了新的文献求助10
3分钟前
3分钟前
alandan完成签到,获得积分10
3分钟前
alandan发布了新的文献求助10
3分钟前
睡不醒完成签到 ,获得积分10
3分钟前
urah关注了科研通微信公众号
3分钟前
深情的从丹完成签到,获得积分10
4分钟前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 2000
Sex, Aging, and Death in a Medieval Medical Compendium: Trinity College Cambridge MS R.14.52, Its Texts, Language, and Scribe 500
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
基于结构调控的功能化水诱导发电材料与器件研究 500
基于界面调控的高效湿气发电材料与器件研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8190214
求助须知:如何正确求助?哪些是违规求助? 9577348
关于积分的说明 21852358
捐赠科研通 7788667
什么是DOI,文献DOI怎么找? 3436310
关于科研通互助平台的介绍 2560076
邀请新用户注册赠送积分活动 2482902